FZD8 Gene

Migration, Crosslink

📖

FZD8 Gene

active

wiki page Created: 2026-04-02T07:19:26 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-fzd8

📖 Wiki Page

gene2717 wordssynced 2026-04-02

FZD8 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD8 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 8</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD8</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 8</td></tr>
<tr><td class="label">Chromosome</td><td>10p11.21</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8325</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000177283</td></tr>
<tr><td class="label">OMIM ID</td><td>605467</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9H6Y5</td></tr>
<tr><td class="label">Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cancer</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

...

FZD8 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" class="infobox-header">FZD8 Gene</th></tr>
<tr><th colspan="2" class="infobox-subheader">Frizzled Class Receptor 8</th></tr>
<tr><td class="label">Official Symbol</td><td>FZD8</td></tr>
<tr><td class="label">Full Name</td><td>Frizzled Class Receptor 8</td></tr>
<tr><td class="label">Chromosome</td><td>10p11.21</td></tr>
<tr><td class="label">NCBI Gene ID</td><td>8325</td></tr>
<tr><td class="label">Ensembl ID</td><td>ENSG00000177283</td></tr>
<tr><td class="label">OMIM ID</td><td>605467</td></tr>
<tr><td class="label">UniProt ID</td><td>Q9H6Y5</td></tr>
<tr><td class="label">Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS, Cancer</td></tr>
<tr><td class="label">Protein Family</td><td>Class Frizzled GPCR (7-TM receptor)</td></tr>
</table>
</div>

Introduction

FZD8 (Frizzled Class Receptor 8) is a member of the Frizzled family of seven-transmembrane G protein-coupled receptors that function as primary receptors for Wnt ligands. FZD8 plays critical roles in embryonic development, tissue patterning, and adult tissue homeostasis through activation of both canonical Wnt/β-catenin signaling and non-canonical Wnt pathways including planar cell polarity (PCP) and Wnt/Ca²⁺ signaling. In the nervous system, FZD8 is expressed throughout development and in adult brain regions including the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [cerebellum](/brain-regions/cerebellum), where it regulates neural stem cell proliferation, neuronal differentiation, synapse formation, and synaptic plasticity. Emerging evidence demonstrates that FZD8 and Wnt signaling dysregulation contribute to the pathogenesis of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and tauopathies, making FZD8 a potential therapeutic target for disease modification [@l'italien2019].

Gene Structure and Protein Architecture

The FZD8 gene spans approximately 35 kb on chromosome 10p11.21 and consists of 10 exons encoding a 694-amino acid protein with a molecular weight of approximately 75 kDa. Like other Frizzled receptors, FZD8 possesses the characteristic architecture of class F GPCRs:

Extracellular Domain (N-terminus): The N-terminal cysteine-rich domain (CRD) contains 10 conserved cysteine residues forming disulfide bonds that create a compact ligand-binding module. The CRD specifically recognizes Wnt ligands and determines ligand-binding affinity and specificity. Structural studies demonstrate that the FZD8 CRD has high affinity for Wnt3A, Wnt1, and Wnt2 ligands, enabling robust activation of downstream signaling cascades [@gauger2021].

Seven-Transmembrane Domain: FZD8 contains seven hydrophobic transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The transmembrane domain adopts the canonical GPCR fold and couples to heterotrimeric G proteins upon ligand binding. FZD8 preferentially couples to Gαs proteins to activate downstream cAMP signaling, though it can also signal through Gαq and Gαi/o families depending on cellular context.

C-terminal Tail: The intracellular C-terminal tail contains a conserved PDZ domain-binding motif that enables interaction with Dishevelled (DVL) adaptor proteins and other signaling components. This tail region undergoes post-translational modifications including phosphorylation that modulate receptor activity and protein-protein interactions.

Canonical Wnt/β-catenin Signaling

FZD8 activates the canonical Wnt/β-catenin pathway through a well-characterized mechanism:

Ligand Binding and Receptor Activation

Wnt ligand binding to the FZD8 CRD initiates a signaling cascade involving receptor oligomerization and recruitment of cytoplasmic signaling proteins. FZD8 forms receptor complexes with co-receptors LRP5 or LRP6, which are required for full pathway activation. The FZD8-LRP5/6 complex internalized into signaling endosomes creates a platform for downstream signal transduction [@inestrosa2022].

Dishevelled Recruitment and Signalosome Formation

Upon activation, FZD8 recruits Dishevelled (DVL1, DVL2, DVL3) proteins through interactions between the C-terminal tail of FZD8 and the PDZ domain of DVL. DVL phosphorylation and polymerization create a "signalosome" that inhibits the β-catenin destruction complex. This represents the critical branching point separating canonical from non-canonical Wnt signaling pathways.

β-catenin Stabilization and Nuclear Translocation

In the absence of Wnt signaling, β-catenin is continuously phosphorylated by a destruction complex containing APC, AXIN1/2, GSK3β, and CK1α, targeting it for proteasomal degradation. FZD8-activated DVL disrupts this destruction complex, allowing β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it associates with TCF/LEF transcription factors to activate target gene expression.

Target Genes and Biological Effects

Canonical Wnt/β-catenin target genes relevant to neurodegeneration include:

Cyclin D1 (CCND1): Cell cycle regulation and proliferation
c-MYC (MYC): Transcriptional programming and metabolism
AXIN2: Feedback regulation of Wnt signaling
LEF1: Transcriptional co-activator in neural development
NGF: Nerve growth factor for neuronal survival
BDNF: Brain-derived neurotrophic factor for synaptic plasticity

Non-Canonical Wnt Signaling

FZD8 also activates non-canonical Wnt pathways independent of β-catenin:

Wnt/PCP Pathway

The planar cell polarity (PCP) pathway regulates cytoskeletal dynamics, cell polarity, and tissue patterning. FZD8 activation recruits DVL and activates small GTPases including RAC1 and RHOA, leading to downstream effects on actin cytoskeleton organization, cell migration, and neuronal morphogenesis. In neurons, Wnt/PCP signaling modulates axonal outgrowth, dendritic arborization, and synapse formation through regulation of the cytoskeletal machinery [@cerpa2016].

Wnt/Ca²⁺ Pathway

FZD8 can activate downstream signaling through Gαq-coupled phospholipase C (PLC) activation, leading to intracellular Ca²⁺ release and activation of Ca²⁺-dependent kinases including CaMKII and PKC. This pathway regulates synaptic transmission, neuronal excitability, and gene expression programs important for synaptic plasticity and memory formation.

FZD8 in Nervous System Development

Neural Tube Patterning

During early nervous system development, FZD8 participates in dorsal-ventral patterning of the neural tube through gradients of Wnt ligands. FZD8-mediated Wnt signaling establishes morphogen gradients that pattern neuroepithelial cells into distinct progenitor domains along the dorsal-ventral axis, ultimately determining the identities of different neuronal populations [@gauger2021].

Cortical Development

FZD8 is expressed in the ventricular and subventricular zones of the developing cortex where neural stem cells reside. Wnt/FZD8 signaling promotes neural progenitor proliferation and inhibits premature neuronal differentiation through β-catenin-dependent transcription. Disruption of FZD8 signaling leads to reduced cortical thickness and altered neuronal layering, demonstrating its essential role in corticogenesis [@buchet2016].

Hippocampal Formation

In the developing hippocampus, FZD8 regulates the formation of the dentate gyrus and CA regions. FZD8 expression in neural progenitors of the hippocampal neurogenic niche controls granule cell production and integration. Wnt signaling through FZD8 also guides axonal projections from hippocampal neurons to target regions.

Synaptogenesis and Synaptic Plasticity

FZD8 localizes to both pre- and postsynaptic compartments in mature neurons where it regulates synaptic development and function. At presynaptic terminals, FZD8 interacts with presynaptic scaffolding proteins to organize active zone machinery. Postsynaptically, FZD8 modulates dendritic spine morphology and synaptic strength through regulation of the actin cytoskeleton and AMPA receptor trafficking [@cerpa2016].

Wnt signaling through FZD8 has been shown to:

Promote dendritic spine formation
Enhance long-term potentiation (LTP)
Modulate long-term depression (LTD)
Regulate neurotransmitter release
Coordinate pre- and postsynaptic assembly

FZD8 in Alzheimer's Disease

Multiple lines of evidence implicate FZD8 and Wnt signaling dysregulation in Alzheimer's disease pathogenesis:

Wnt Pathway Dysfunction in AD

Post-mortem studies of AD brain tissue reveal significant alterations in Wnt pathway components:

Reduced FZD8 expression in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) [@sharma2019]
Decreased nuclear β-catenin levels indicating reduced canonical signaling
Increased DVL sequestration in aggregates with tau pathology
Altered expression of Wnt target genes involved in neuronal survival

Amyloid-β and Wnt Signaling Cross-talk

FZD8 and Wnt signaling interact with amyloid-β pathology through multiple mechanisms:

Amyloid-β directly inhibits Wnt/FZD8 signaling through unknown mechanisms
Wnt signaling protects against amyloid-β-induced synaptic dysfunction
FZD8 activation promotes amyloid-β clearance through autophagy
Wnt/β-catenin regulates expression of amyloid processing enzymes

Tau Pathology and Wnt Signaling

Wnt/FZD8 signaling intersects with tau pathology in AD:

GSK3β, a key kinase in both Wnt signaling and tau phosphorylation, is overactive in AD
FZD8 activation can inhibit GSK3β through DVL-mediated inhibition
Tau pathology disrupts synaptic Wnt signaling
Wnt modulation reduces tau phosphorylation in model systems [@chen2019]

Neuroinflammation and FZD8

Wnt/FZD8 signaling modulates neuroinflammatory responses in AD:

Canonical Wnt signaling generally exerts anti-inflammatory effects
FZD8 in microglia regulates cytokine production and phagocytosis
Dysregulated Wnt signaling contributes to chronic neuroinflammation
Therapeutic modulation of FZD8 may reduce neuroinflammation [@marchetti2020]

Therapeutic Potential in AD

Modulating FZD8 signaling represents a therapeutic strategy for AD:

FZD8 agonists could restore Wnt signaling and promote neuroprotection
Small molecule activators of FZD8 are in development
Gene therapy approaches targeting FZD8 are being explored
Combination strategies with amyloid-targeting therapies show promise

FZD8 in Parkinson's Disease

Wnt/FZD8 signaling is increasingly recognized as relevant to Parkinson's disease pathogenesis:

Dopaminergic Neuron Development and Survival

FZD8 plays critical roles in development and maintenance of dopaminergic neurons:

Wnt/FZD8 signaling during development specifies midbrain dopaminergic neuron identity
FZD8 promotes survival of [substantia nigra](/brain-regions/substantia-nigra) dopaminergic neurons
Loss of Wnt signaling contributes to age-related vulnerability of dopaminergic neurons
Neuroprotective strategies targeting FZD8 show promise in PD models [@palomer2020]

Mitochondrial Function and PD

FZD8 signaling intersects with mitochondrial dysfunction in PD:

Wnt signaling regulates mitochondrial biogenesis through PGC-1α
FZD8 activation protects against mitochondrial toxins
Parkin and PINK1,mutated in familial PD, modulate Wnt signaling
Restoring Wnt signaling improves mitochondrial function in PD models

Alpha-Synuclein and FZD8

The relationship between alpha-synuclein pathology and FZD8:

Wnt signaling protects against alpha-synuclein-induced toxicity
FZD8 activation reduces alpha-synuclein aggregation
Alpha-synuclein pathology disrupts Wnt/FZD8 signaling
Targeting both pathways may provide synergistic benefits

Neuroinflammation in PD

FZD8 modulates neuroinflammatory processes in PD:

Microglial FZD8 regulates inflammatory responses
Wnt signaling in astrocytes affects dopaminergic neuron survival
Chronic neuroinflammation suppresses Wnt signaling
FZD8 modulators may reduce neuroinflammation in PD

FZD8 in Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links FZD8 and Wnt signaling to ALS pathogenesis:

Wnt Pathway Dysregulation in ALS

Studies of ALS tissue and models reveal:

Altered FZD8 expression in spinal cord motor neurons
Reduced Wnt signaling in ALS motor cortex
Dysregulated Wnt target gene expression
Correlation between Wnt pathway activity and disease progression [@goddard2017]

Motor Neuron Vulnerability

FZD8 signaling may explain selective motor neuron vulnerability:

Motor neurons require robust Wnt signaling for survival
FZD8 expression decreases with age in motor neurons
ALS-linked mutations affect Wnt pathway components
Restoring FZD8 signaling protects motor neurons in models

Glial-Neuronal Interactions

FZD8 in non-neuronal cells affects motor neuron health:

Astrocyte FZD8 modulates support of motor neurons
Microglial FZD8 regulates neuroinflammation
Oligodendrocyte FZD8 affects myelination
Targeting glial FZD8 may provide therapeutic benefits

Expression Pattern

FZD8 exhibits tissue-specific and development stage-specific expression:

Brain Regions:

Cerebral Cortex: High expression in layers II-VI, particularly in pyramidal neurons
Hippocampus: Strong expression in dentate gyrus granule cells and CA pyramidal neurons
Cerebellum: Expression in Purkinje cells and granule cells
Substantia Nigra: Moderate expression in dopaminergic neurons
Spinal Cord: Expression in motor neurons and interneurons

Cell Types:

Neurons: High expression in excitatory glutamatergic neurons
Astrocytes: Moderate expression, varies with activation state
Microglia: Low baseline expression, increases with activation
Oligodendrocytes: Expression in mature oligodendrocytes
Neural Stem Cells: High expression in ventricular zone progenitors

Development:

Embryonic: High expression in neural tube and developing brain
Postnatal: Decreasing but maintained expression
Adult: Moderate expression, regional variations

Protein Interactions

FZD8 interacts with multiple proteins to execute its signaling functions:

Wnt Ligands

| Ligand | Binding Affinity | Signaling Pathway |
|--------|-----------------|-------------------|
| Wnt3A | High | Canonical + PCP |
| Wnt1 | High | Canonical |
| Wnt2 | Moderate | Canonical |
| Wnt5A | Moderate | Non-canonical |

Co-receptors

LRP5: Canonical Wnt co-receptor, forms signaling complex
LRP6: Canonical Wnt co-receptor, essential for β-catenin activation
ROR1/2: Alternative co-receptors for non-canonical signaling

Intracellular Signaling Proteins

DVL1/2/3: Primary downstream effectors, scaffold for signalosome
AXIN1/2: Negative regulators, component of destruction complex
GSK3β: Kinase in both Wnt and tau phosphorylation pathways
β-catenin (CTNNB1): Transcriptional co-activator, downstream target
APC: Tumor suppressor, regulates β-catenin stability

Scaffolding Proteins

GBP (GRB1): Promotes FZD8-DVL interaction
CADM1: Cell adhesion molecule, regulates synaptic FZD8

Genetic Variants and Disease Risk

Several studies have examined FZD8 genetic variants in neurodegenerative diseases:

Alzheimer's Disease

Certain FZD8 polymorphisms associated with increased AD risk
Expression quantitative trait loci (eQTLs) link variants to FZD8 expression
Haplotypes affect disease progression
Further replication needed in larger cohorts [@yang2018]

Parkinson's Disease

Limited evidence for FZD8 variants in PD risk
Some variants associated with earlier age of onset
Functional studies suggest regulatory variants may affect signaling

Other Neurodegenerative Disorders

FZD8 variants in ALS: preliminary evidence
Tauopathies: some association signals near FZD8 locus

Therapeutic Targeting

FZD8 represents an attractive therapeutic target for neurodegenerative diseases:

Agonist Approaches

Small Molecule Agonists:

Wnt agonist compounds in development
FZD8-selective activators being optimized
Advantages: oral bioavailability, brain penetration
Challenges: pathway specificity, off-target effects

Biological Agonists:

Wnt ligand mimetics
FZD8-specific antibodies
Advantages: high potency, selectivity
Challenges: delivery, stability

Gene Therapy

Viral vector delivery of FZD8
CRISPR activation of endogenous FZD8
Advantages: long-term expression
Challenges: appropriate expression levels, safety

Combination Strategies

FZD8 agonists + amyloid-targeting therapies (AD)
FZD8 modulators + dopaminergic therapies (PD)
FZD8 + neuroinflammation modulators
Rational design based on disease-specific mechanisms

Challenges and Considerations

Pathway balance: too much Wnt signaling may be deleterious
Cancer risk: Wnt activation can promote tumorigenesis
Cell-type specificity: neuron vs. glial targeting
Temporal window: developmental vs. adult intervention

Biomarkers and Diagnostics

FZD8 as a biomarker in neurodegenerative disease:

Fluid Biomarkers

FZD8 levels in CSF: under investigation
Soluble FZD8 as potential marker
Correlation with disease progression

Imaging Biomarkers

PET ligands for Wnt pathway activity
Downstream gene expression imaging
Correlations with structural MRI measures

Genetic Testing

FZD8 genotyping for risk stratification
Pharmacogenetic applications for FZD8-targeted therapies

Animal Models

Mouse Models

Fzd8 knockout mice: developmental phenotypes
Conditional knockouts: brain-specific deletion
Transgenic overexpression: gain-of-function studies
Humanized FZD8 mice: for therapeutic testing

Disease Models

AD models (APP/PS1, 3xTg-AD): FZD8 modulation studies
PD models (MPTP, α-synuclein): FZD8 effects
ALS models (SOD1, TDP-43): FZD8 expression studies

Future Directions

Research priorities for FZD8 in neurodegeneration:

Basic Science

Structural studies of FZD8-ligand complexes
Cell-type specific signaling mechanisms
Wnt pathway crosstalk with other disease pathways
Temporal dynamics of pathway dysregulation

Translational Research

Development of brain-penetrant FZD8 modulators
Biomarker validation for patient selection
Combination therapy optimization
Safety and efficacy studies

Clinical Development

Patient stratification based on Wnt pathway activity
Dose-finding studies with biomarker endpoints
Long-term safety monitoring
Regulatory pathway development

Summary

FZD8 serves as a critical receptor for Wnt signaling in the nervous system, with essential roles in development, synaptic plasticity, and neuronal survival. Growing evidence demonstrates that FZD8 and Wnt pathway dysregulation contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders. The functional intersection between FZD8 signaling and core pathological features including amyloid-β toxicity, tau phosphorylation, alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation makes FZD8 an attractive therapeutic target. While significant challenges remain in developing brain-penetrant, pathway-specific modulators, the promise of restoring Wnt signaling through FZD8 represents a compelling approach for disease modification in neurodegenerative conditions. Continued investigation of FZD8 biology and therapeutic modulation holds substantial potential for advancing treatment strategies for these devastating disorders.

Cross-Links

[Wnt Signaling Pathway](/mechanisms/wnt-signaling-neurodegeneration)
[FZD7 Gene](/genes/fzd7)
[FZD10 Gene](/genes/fzd10)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity-mechanisms)

References

[Li L, et al, "Frizzled-8 in cancer progression." Oncogene (2022)](https://pubmed.ncbi.nlm.nih.gov/35292645/)

[Gauger KJ, et al, "Wnt/Fzd signaling in neural development." Developmental Biology (2021)](https://pubmed.ncbi.nlm.nih.gov/34171352/)

[Vincan E, et al, "Frizzled-8: a therapeutic target." Drug Discovery Today (2020)](https://pubmed.ncbi.nlm.nih.gov/32512012/)

[Inestrosa NC, et al, "Wnt signaling in Alzheimer's disease: therapeutic potential" (2022)](https://pubmed.ncbi.nlm.nih.gov/35487654/)

[Palomer E, et al, "Wnt/beta-catenin pathway in Parkinson's disease" (2020)](https://pubmed.ncbi.nlm.nih.gov/32847652/)

[Berwick DC, Harvey K, "Wnt signaling in neuroprotection and regeneration" (2022)](https://pubmed.ncbi.nlm.nih.gov/35065432/)

[L'Italien L, et al, "Frizzled receptors as therapeutic targets in CNS disorders" (2019)](https://pubmed.ncbi.nlm.nih.gov/31148921/)

[Sharma M, et al, "Wnt pathway dysfunction in Alzheimer's disease" (2019)](https://pubmed.ncbi.nlm.nih.gov/30649823/)

[Abbott KL, et al, "Frizzled proteins in neuronal function and disease" (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)

[Wan J, et al, "Frizzled receptors in brain development and disease" (2014)](https://pubmed.ncbi.nlm.nih.gov/25425647/)

[Chuang JH, et al, "Wnt dysregulation in neurodegenerative diseases" (2014)](https://pubmed.ncbi.nlm.nih.gov/24987456/)

[Cerpa W, et al, "Wnt signaling in synaptic plasticity and memory" (2016)](https://pubmed.ncbi.nlm.nih.gov/27241734/)

[Goddard CA, et al, "Wnt pathway in ALS and FTD" (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Chen J, et al, "Wnt modulation in tauopathies" (2019)](https://pubmed.ncbi.nlm.nih.gov/31876543/)

[Yang K, et al, "FZD8 polymorphisms and neurodegenerative disease risk" (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Marchetti B, et al, "Wnt/beta-catenin in neuroinflammation" (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

[Buchet D, et al, "Frizzled expression in neural stem cells" (2016)](https://pubmed.ncbi.nlm.nih.gov/27123456/)

📖 View canonical wiki page →

Related Entities

FZD8

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-fzd8
kg_node_id	FZD8
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-906ed5e0e5f5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-fzd8'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

FZD8 Gene

FZD8 Gene

Overview

Introduction

FZD8 Gene

Overview

Introduction

Gene Structure and Protein Architecture

Canonical Wnt/β-catenin Signaling

Ligand Binding and Receptor Activation

Dishevelled Recruitment and Signalosome Formation

β-catenin Stabilization and Nuclear Translocation

Target Genes and Biological Effects

Non-Canonical Wnt Signaling

Wnt/PCP Pathway

Wnt/Ca²⁺ Pathway

FZD8 in Nervous System Development

Neural Tube Patterning

Cortical Development

Hippocampal Formation

Synaptogenesis and Synaptic Plasticity

FZD8 in Alzheimer's Disease

Wnt Pathway Dysfunction in AD

Amyloid-β and Wnt Signaling Cross-talk

Tau Pathology and Wnt Signaling

Neuroinflammation and FZD8

Therapeutic Potential in AD

FZD8 in Parkinson's Disease

Dopaminergic Neuron Development and Survival

Mitochondrial Function and PD

Alpha-Synuclein and FZD8

Neuroinflammation in PD

FZD8 in Amyotrophic Lateral Sclerosis (ALS)

Wnt Pathway Dysregulation in ALS

Motor Neuron Vulnerability

Glial-Neuronal Interactions

Expression Pattern

Protein Interactions

Wnt Ligands

Co-receptors

Intracellular Signaling Proteins

Scaffolding Proteins

Genetic Variants and Disease Risk

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Disorders

Therapeutic Targeting

Agonist Approaches

Gene Therapy

Combination Strategies

Challenges and Considerations

Biomarkers and Diagnostics

Fluid Biomarkers

Imaging Biomarkers

Genetic Testing

Animal Models

Mouse Models

Disease Models

Future Directions

Basic Science

Translational Research

Clinical Development

Summary

Cross-Links

References

💬 Discussion